Introduction

32
Genome wide association studies (GWAS) can help gain numerous insights on the genetic 33 basis of complex diseases, and ultimately contribute to personalized risk prediction and pre-34 cision medicine [1] [2] [3] [4] . However, fine-mapping the exact causal variants is challenging due to 35 linkage disequilibrium (LD) and the lack of ability to interpret the function of noncoding 36 variants, which contribute to about 90% of the current GWAS catalog (40.7% intergenic 37 and 48.6% intronic; [5] ). On the other hand, several lines of evidence have been proposed 38 to help interpret non-coding genetic signals, in order to gain insights into potential regula-39 tory functions. In particular, epigenomic annotations can pinpoint locations of biochemical 40 activity indicative of cis-regulatory functions [6, 7] . Indeed, comparison with genome-wide 41 annotations of putative regulatory elements has shown enrichment of GWAS variants in 42 enhancer-associated histone modifications, regions of open chromatin, and conserved non-43 coding elements [3, 6, [8] [9] [10] [11] [12] , indicating they may play gene-regulatory roles. These enrich-44 ments have been used to predict relevant cell types and non-coding annotations for specific 45 traits [6, 9, 13] . Furthermore, many complex traits potentially share causal mechanisms such 46 as autoimmune diseases [14, 15] and psychiatric disorders [16, 17] . Thus, methods that jointly sponding GWAS p-values as Beta distributions with an option of using one or more sets 60 of annotations to improve the power detecting causal variants [19] . Although useful, these 61 methods are often designed to simultaneously operate on a small number of independent 62 annotations due to some computational constraints. Moreover, most methods only operate 63 on one trait at a time whereas exploiting the correlation between traits at the epigenomic 64 annotation level may prove useful for shared causal mechanisms that go beyond the level of 65 individual variants.
66
In this article, we describe a novel Bayesian framework called RiVIERA-beta (Risk parameters [20] . We first use simulation to demonstrate the utility of RiVIERA-beta in 74 prioritizing driver variants and detecting functional epigenomic annotations. We then apply
75
RiVIERA-beta to some of the most well-powered GWAS datasets, consisting of 9 immunolog-76 ical disorders from ImmunoBase [15] and Schizophrenia 2014 data from Psychiatric Genomic
77
Consortium [21] . To infer tissue-specific epigenomic enrichments, we utilize the largest com-78 pendium of epigenomic annotations to date from ENCODE/Roadmap Consortia, consisting 79 of 848 annotations including 8 major epigenomic marks across 127 distinct cell types [7] .
80
This allows us to revisit the GWAS of these 10 common complex disorders by inferring their 81 underlying regulatory variants implicated at the tissue-specific epigenomic contexts.
82
MATERIALS AND METHODS
83
GWAS summary statistics
84
The GWAS summary statistics for the nine immune diseases were obtained from ImmunoBase 
where w kd ∈ w d denotes the linear coefficient or the influence of the k th epigenomic mark 138 affecting disease d and w 0d is the linear bias.
139
We assume that epigenomic causal effect w kd follows a multivariate Gaussian distribution with zero mean and unknown covariance:
where Λ w is a D × D inverse covariance matrix Λ w = Σ prior belief on the correlation between any two diseases of interests.
145
Additionally, the bias w 0d follows a Gaussian distribution with unknown variance and mean determined based on our prior belief of the causal fraction π 0 :
where logit(π 0 ) = log
. By default, we set π 0 to 0.01, implying that 1% of the SNPs in 146 the risk loci are expected to be causal when no functional enrichment. We set α = 0.01 and 147 β = 0.0001 to enable a broad hyperprior for w 0d .
148
Notably, w kd can be interpreted as enrichment coefficient for annotation k in disease d,
149
where a positive w kd will increase the causal prior π vd when e vk = 1. During the training,
150
however, w kd may become negative, which makes the interpretation difficult. Thus, we 151 constrain w kd to be non-negative values, which involves imposing infinitely high potential 152 energy for negative w kd . More details are described in Supplementary Text 1.
153
Inference of variant causality c vd given prior π vd and model parameters µ d , φ d
154
Because the target association variable a vd for variant v in disease d represents p-values, which are continuous and restricted to the interval (0, 1), we assume that it follows a Beta distribution with unknown mean µ d and unknown precision φ d :
Note that we re-parameterize Beta density function from the traditional "rate" p and "shape" q parameters, and instead use mean µ = p/(p + q) and precision φ = p + q, as per [24, 25] . Specifically, the density function of association variable a vd is defined as follows:
Further, we let the mean µ d and precision φ d follow Beta and uniform prior, respectively:
where the hyperparameters (µ 0 , φ 0 ) reflect apriori belief on the p-value signal of a causal 155 variant. By default, we set µ 0 = 0.1 and φ 0 = 2. If φ max = ∞, φ follows an improper prior.
156
Because it is unlikely to have a very large φ, by default, we set φ max to 1000. The complete likelihood density function treating c vd as missing values is defined as:
The logarithmic joint posterior density function is then:
In principle, causality is inferred by integrating out all nuisance parameters: 
where S is the sample variance of W, i.e., S = W T W.
170
Similarly, we sample λ 0d from Gamma posterior distribution: Due to co-linearity among the epigenomic annotations, directly using w kd to assess the epigenomic enrichment for annotation k may be misleading. We propose an heuristic approach to assess the log fold-enrichment of the full prior model over the alternative prior with the effect of annotation k for disease d removed (i.e., w d\k , w kd = 0):
where p(c vd |w based on the ranking of its lower bound f kd (i.e., the 2.5% quantile of f kd ). 
199
GWAS simulation
200
To assess the power of the proposed fine-mapping model in identifying causal variants and 201 compare it with existing methods, we implemented a simulation pipeline adapted from [18] .
202
Briefly, the simulation can be divided into three stages (1) RiVIERA-beta to large matrices very efficiently with complied code and having much lesser 226 memory overhead than a naïve R implementation. RiVIERA-beta is available at Github
227
(https://github.mit.edu/liyue/rivieraBeta).
228
RESULTS
229
RiVIERA model overview
230
The fundamental hypothesis of our model is that non-coding disease associations are driven 231 by disruption of regulatory elements of common activity patterns (e.g., motifs of sequence- RiVIERA-beta are GWAS summary statistics in terms of p-values and a set of discrete or 238 continuous epigenomic annotations (Fig. 1a) . In this study, we used binary signals to ease in-
239
terpretation of the functional enrichments. We train RiVIERA-beta by repeatedly sampling 240 one locus at each iteration to efficiently learn the intrinsic (i.e., locus-independent) causal 241 signals. we observe that our model is well calibrated (Fig. S2) scores (phastCons46way obtained from UCSC database) across most traits (Fig. 4 CONS) . our proposed RiVIERA-beta model ( Fig. 4 ; Supplementary Table S3) .
331
Gene-centric analysis revealed enrichment for meaningful biological 
344
Intriguingly, we observed a highly significant enrichment for keratinization (GO:0031424)
345
and epidermis (e.g., skin) development (GO:0008544) exclusively for Psoriasis. In particular,
346
17 genes among the 241 credible genes belong to keratinization and epidermis development, 347 which contain in total 49 and 121 genes, respectively (q < 9 × 10 −18 , q < 2 × 10 −10 ).
348
Indeed, Psoriasis is mainly characterized as a chronic skin disease with epidermal hyper-349 proliferation [39, 40] . In contrast, there are only 6 out of 157 GWAS-genes are defined in 350 each of two GO categories (q < 0.001).
351
To further ascertain the RiVIERA-beta fine-mapping results, we created a visualization 352 scheme for each of the 469 risk loci across 10 traits examined ( Supplementary Fig. S6 ). estimates.
364
Consistent with the overall enrichment results (Fig. 3) prior that takes into account the sampled disease covariance (Materials and methods).
388
As a results, RiVIERA-beta sampled correlated epigenomic weights between traits more 389 frequently compared to the single-trait model.
390
We constructed the 95% credible sets for each trait using the disease-specific PPA derived is more consistent with the epigenomic correlation pattern between the related immune traits.
405
We also repeated the GO enrichment analysis on the 95% credible set and found that the 406 enriched GO terms were mostly immune-specific biological processes and consistent with the 407 above single-trait analyses (Supplementary Fig. S7 ; Supplementary Table S7 18, 199-209 (2015) . 
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Figure Legends The three other panels illustrate hypergeometric enrichments in terms of the -log10 q-values corrected for multiple testing over the 10 traits of the selected variants for GTEx whole blood eQTL located within transcription factor binding sites based on sequence motif (TFBS) (eQTL+TFBS) and genomic digital footprint (DGF) (eQLT+DGF), and eQTL in both TFBS and DGF (eQTL+TFBS+DGF). Enrichments for eQLT using credible SNPs constructed from multi-trait joint inference. Credible SNPs for each trait were constructed based on PPA inferred by the joint RiVIERA-beta model over the 9 immune traits using 174 annotations, which are the union of the top 43 annotations detected from each trait individually. We then assessed the hypergeometric enrichments of the 95% credible sets for the GTEx whole-blood eQTL that are within DNA hypersensitive sites as defined by the genomic digital footprint data [38] . We compared these enrichment scores derived from the multi-trait model (cred snp mt) to the enrichments derived from the single-trait models either running on 43 annotations (cred snp st43) or on the 174 annotations (cred snp st174). The latter was included to control for the improvements due to the increased number of annotations (from 43 to 174). We investigated 10 GWAS traits as listed above. Abbrev: abbreviation of the trait names; Total: total number of SNPs in the risk loci with imputed and observed summary statistics; Loci: total number of risk loci for each trait; gwSNPs: SNPs that pass GWAS cutoff p < 5e-8; cSNP st: total number of SNPs that are included into the 95% credible set based on single-trait risk inference using RiVIERA-beta; cSNP mt: SNPs in 95% credible set constructed based on multi-trait joint risk inference using RiVIERA-betaacross the 9 immune traits (without SCZ2). 
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